Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)

This study has been completed.
Information provided by (Responsible Party):
Hiroaki Kazui, Osaka University Identifier:
First received: October 20, 2008
Last updated: October 14, 2015
Last verified: October 2015
The purpose of this study is to evaluate change of cerebral glucose metabolism by donepezil therapy and to associate change of glucose metabolism and symptoms.

Condition Intervention
Dementia With Lewy Bodies (DLB)
Drug: Donepezil

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Donepezil Therapy and Changes of Symptoms and Glucose Metabolism in Patients With Dementia With Lewy Bodies (DLB)

Resource links provided by NLM:

Further study details as provided by Osaka University:

Primary Outcome Measures:
  • FDG-PET [ Time Frame: 14 weeks ]

Secondary Outcome Measures:
  • Cognitive function, psychiatric symptoms, global clinical function, and burden of caregiver [ Time Frame: 14 weeks ]

Enrollment: 24
Study Start Date: October 2008
Study Completion Date: February 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: donepezil Drug: Donepezil
Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
Drug: Donepezil


Ages Eligible for Study:   60 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

DLB patients:

  • who fulfill the diagnostic criteria of DLB
  • 60 to 85 years old
  • right-handed
  • Clinical Dementia Rating (CDR) ≧ 0.5
  • Mini Mental State Examination (MMSE) score from 10 to 26

Normal Controls:

  • who are independent
  • who have no subjective or objective cognitive impairment
  • 60 to 85 years old
  • right-handed
  • MMSE score over 24

Exclusion Criteria:

DLB patients:

  • who have diabetes mellitus
  • who have pathological change on MRI other than brain atrophy
  • who have complication or history of dementia other than DLB, psychiatric disease, and physical disorder that affect brain function
  • who have severe complication of cardiovascular, hepatic, renal, or other diseases unable to secure the safety
  • who have severe digestive ulcus
  • who have severe bronchitic asthma or obstructive lung disease
  • who have no caregiver who knows patient's condition well

Normal Controls:

  • who have diabetes mellitus
  • who have taken donepezil before
  • who have abnormal findings on MRI
  • who have complication or history of brain injury, psychiatric disease, and physical disorder that affect brain function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00776347

Osaka University Hospital
Suita,, Osaka, Japan, 565-0871
Sponsors and Collaborators
Osaka University
Principal Investigator: Hiroaki Kazui, MD, PhD Osaka University
  More Information

Additional Information:
Responsible Party: Hiroaki Kazui, M.D,Ph.D, Osaka University Identifier: NCT00776347     History of Changes
Other Study ID Numbers: OSK-08096
Study First Received: October 20, 2008
Last Updated: October 14, 2015

Keywords provided by Osaka University:
Dementia with Lewy bodies (DLB)

Additional relevant MeSH terms:
Lewy Body Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Parkinsonian Disorders
Basal Ganglia Diseases
Movement Disorders
Neurodegenerative Diseases
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents processed this record on May 22, 2017